pyrazinamidese activity, autoagglutinability, presence of a 40-to 50-megadalton plasmid, production of heat-stable enterotoxin, and mouse lethality. AUl isolates tested had pyrazinamidase activity, and none were autoagglutinable. However, one isolate possessed a 40-megadalton plasmid. None produced enterotoxin or were lethal for mice. Review of the medical histories of the patients revealed that four of the six had diarrhea; however, none had disease typical of that caused by Y. enterocolitica. Our data confirmed the limited pathogenic potential of Y. intermedia and suggested that its isolation was without clinical significance in our patients. Conventional biochemical tests were required for reliable identification of Y. intermedia.
Yersinia intermedia was defined biochemically and genetically as a species in 1980 (7) . Acid production from amethyl-D-glucoside, D-melibiose, D-raffinose, and Lrhamnose and utilization of citrate help distinguish it from Y. enterocolitica and other Yersinia species.
The pathogenic potential of Y. intermedia for humans has not been well defined, and there are few reports of its isolation from clinical specimens. Bottone et al. (5) isolated bacteria subsequently identified as Y. intermedia from nonmesenteric sources in 12 patients. Of the 321 strains of Y. intermedia studied by Brenner et al. (7) , only 13% were of human origin. Butler et al. (8) x i07 CFU in 0.5 ml. The inoculum was prepared from bacteria grown overnight in brain heart infusion broth at 25°C. The cells were pelleted and suspended in sterile saline to a turbidity equal to a 0.5 McFarland standard. The inoculum was confirmed by agar plate colony counts. The mice were observed daily for 21 days for signs of illness or death.
Patients. The medical records of those patients for whom diarrhea was a presenting symptom were reviewed. The following clinical features were noted: concomitant illness, duration of diarrhea, temperature of >380C, nausea or emesis, abdominal cramps, blood or mucus in the stool, and arthralgias. break of viral gastroenteritis. Patient 6 was the father of an infant who suffered an acute gastrointestinal disease of uncertain etiology.
RESULTS

DISCUSSION
The six strains of Y. intermedia included in this study were all misidentified as Y. enterocolitica by the API 20E system. Delayed utilization of rhamnose, melibiose, and citrate probably accounted for these misidentifications. Our results and those of Baker and Farmer (3) demonstrate that reliable identification of isolates identified as Y. enterocolitica by the API 20E systems requires further testing by conventional biochemical methods. Although the API data base includes the "newer" Yersinia species hitherto referred to as atypical Y. enterocolitica or Y. enterocolitica-like bacteria, our data indicate that larger numbers of Y. intermedia isolates need to be tested to improve the ability of the system to distinguish the species.
One of our isolates of Y. intermedia, strain 4, did not conform to any of the eight biotypes described by Brenner et al. (7) . This strain resembles Y. intermedia in its abilities to ferment rhamnose and a-methyl-D-glucoside and use citrate as a carbon source. However, it failed to produce acid from melibiose and raffinose even after incubation for 14 days. Shayegani et al. (21) described a similar strain isolated from a water sample submitted from Essex County, N.Y. Agbonlahor (1) also reported biochemically similar strains isolated from the feces of five patients with acute diarrheal disease in Lagos, Nigeria. He suggested the strains with the above biochemical pattern be referred to as Y. intermedialike or Y. intermedia biotype 9 until their taxonomic status is clarified.
The clinical significance of Y. intermedia and the other newly described Yersinia species is not well defined. Y. intermedia has been isolated from all parts of the world, with the majority of strains originating from environmental or animal sources (7, 21) . Y. intermedia has only rarely been reported from human stool specimens but has been associated with human wound infections (4) . We chose to assess the pathogenic potential of our Y. intermedia isolates by using assays that have been reported to be indicators of virulence for Y. enterocolitica.
Kandolo and Wauters (14) reported that the pyrazinamidase test was a valuable tool to distinguish potentially pathogenic from nonpathogenic strains of Yersinia sp. The six Y. intermedia strains described in our study were all positive in the pyrazinamidase test, unlike pathogenic strains of Y. enterocolitica, Y. pseudotuberculosis, and Y. pestis.
Autoagglutinability is commonly used as an indicator of Yersinia virulence for mice (15, 16) . A positive autoagglutination test is highly predictive of mouse lethality; however, a nonautoagglutinable, lethal strain has been described (19) . None of the Y. intermedia strains examined by Prpic et al. (19) and Kay et al. (15) were autoagglutinable. In constrast to these findings, Agbonlahor (1) reported that four of five Y. intermedia biotype 9 strains autoagglutinated. None of the isolates of Y. intermedia obtained from our patients were autoagglutinable, including our one biotype 9 strain.
The presence of a 40-to 50-MDa plasmid determines virulence in Y. enterocolitica (9, 18) . However, since both chromosome-and plasmid-determined properties are required for full expression of pathogenic potential, the presence of a plasmid of the appropriate size class is a necessary but not sufficient condition for virulence (12) . The Y. intermedia isolated from patient 3 harbored a 40-MDa plasmid. Prpic et al. (19) found that six of eight Y. intermedia isolates possessed plasmids of 40 to 50 MDa. None of the five Y. intermedia biotype 9 strains examined by Agbonlahor (1) contained plasmids of this molecular mass. Although more strains need to be tested, virulence plasmids apparently are not uncommon in Y. intermedia.
Pai and Mors (17) reported that all of the 43 clinical isolates of Y. enterocolitica they examined were enterotoxigenic when tested in the infant-mouse model. This enterotoxin was shown to be similar to E. coli heat-stable enterotoxin. Kay et al. (15) It was clear from a review of the medical histories that isolation of Y. intermedia from patients 1 and 6 was without clinical significance. Neither patient had gastrointestinal tract symptoms, and the organisms were recovered from surveillance cultures. Although the remaining four patients from whom we recovered Y. intermedia had diarrhea as a presenting symptom, the clinical features were not those typically described for Yersinia infections (6) . Patient 5 complained of transitory left-and right-knee pain concurrent with her diarrhea; however, no joint swelling or stiffness was found. In most cases of Y. enterocolitica-induced polyarthritis, multiple joints become inflamed in rapid succession over a period of 2 to 14 days. Symptoms persist for months in most cases.
The etiology of the diarrhea in our four patients was never firmly established. The fact that cold enrichment was necessary for isolation of Y. intermedia from all of our patients, despite direct plating of feces on medium selective for yersinae, indicated that they were shed in small numbers. Based on the clinical features and in vitro and in vivo assessments of virulence, it seems unlikely that Y. intermedia was involved in the pathogenesis of diarrhea in these patients. However, our data do not completely exclude this possibility.
Important differences in pathogenic potential exist between Y. enterocolitica and Y. intermedia. Because of these differences it is important to distinguish these species reliably. Precise definition and complete biological characterization of Yersinia spp. by clinical microbiologists should help clarify what role, if any, Y. intermedia plays in the pathogenesis of human diarrheal disease.
